What the diagnosis means
"Breast cancer" is several diseases. The biopsy report tells us which one you have, and that drives everything that follows:
- Hormone-receptor status (ER, PR). Cancers that carry oestrogen or progesterone receptors — the majority — can be treated with hormone (endocrine) therapy.
- HER2 status. About one in five breast cancers over-produce the HER2 protein and respond to HER2-targeted antibodies.
- Triple-negative cancers lack all three receptors; chemotherapy, and in some cases immunotherapy, are the main systemic treatments.
- Grade (1–3) describes how abnormal the cells look; Ki-67 estimates how fast they are dividing.
Stage (0–IV) describes size, lymph-node involvement and whether the cancer has spread elsewhere. Most breast cancers in India are still diagnosed at stage II–III, when treatment aims at cure.
Where medical oncology fits
Breast cancer care is a team effort. The surgical oncologist removes the tumour (breast-conserving surgery or mastectomy, with lymph-node assessment); the radiation oncologist treats the breast or chest wall and nodes when indicated; the medical oncologist plans and delivers the systemic treatments — chemotherapy, hormone therapy, HER2-targeted therapy, newer targeted drugs and immunotherapy — and coordinates the sequence. For many patients, systemic treatment is what most reduces the risk of the cancer returning.
When systemic treatment is considered
- Before surgery (neoadjuvant): for larger or node-positive tumours, for most HER2-positive and triple-negative cancers, and when a smaller operation may become possible. Response to pre-operative treatment also gives information that guides treatment afterwards.
- After surgery (adjuvant): hormone therapy for most ER-positive cancers (typically 5–10 years); chemotherapy where the risk of recurrence justifies it — for some ER-positive cancers a gene-expression test can help decide; HER2-targeted therapy for HER2-positive cancers, usually for a year.
- Metastatic (stage IV): treatment aims at control and quality of life over the long term. Many patients live for years on sequential hormone, targeted and chemotherapy options; the plan is reviewed at each change.
How decisions are made
The receptor results and grade, the stage, your menopausal status, your general health and your own priorities all feed into a plan that is discussed in a multidisciplinary meeting. A genetic (BRCA) test is suggested for younger patients, those with a family history, and triple-negative cancers, because it can change both surgery and drug choices. If any of these results are missing from your report, ask — they are worth waiting for.
What to expect
Chemotherapy is usually 4–8 cycles over 3–6 months; HER2 antibodies are given every three weeks for a year; hormone tablets are taken daily for years. Side effects differ by treatment and are covered on the chemotherapy, hormone therapy and targeted therapy pages. Fertility, menopause symptoms, heart monitoring with HER2 drugs, and bone health on long-term hormone therapy are discussed before treatment starts.
Questions to ask
- What are my ER, PR, HER2 and grade results, and what do they mean for my options?
- Should treatment come before or after surgery in my case?
- Is a genetic test recommended for me or my family?
- What is the goal of the systemic treatment, and what is the expected benefit in my situation?
- How will treatment affect fertility, work and daily life?
Preparing for your consultation
Bring the biopsy report with receptor results, mammogram/ultrasound/MRI and any staging scans with reports, surgical notes if surgery has been done, and a medicine list. Note your menstrual/menopausal status and any family history of breast or ovarian cancer.